210 related articles for article (PubMed ID: 32375077)
1. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity.
Liao W; Wang Z; Han Y; Qi Y; Liu J; Xie J; Tian Y; Lei Q; Chen R; Sun M; Tang L; Gong G; Zhao Y
Eur J Med Chem; 2020 Jul; 197():112309. PubMed ID: 32375077
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing sulfonamido as potential PI3Kα inhibitors.
Yin Y; Hu JQ; Wu X; Sha S; Wang SF; Qiao F; Song ZC; Zhu HL
Bioorg Med Chem; 2019 Jun; 27(11):2261-2267. PubMed ID: 31029551
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K
Chen R; Wang Z; Sima L; Cheng H; Luo B; Wang J; Guo B; Mao S; Zhou Z; Peng J; Tang L; Liu X; Liao W
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2155638. PubMed ID: 36650905
[TBL] [Abstract][Full Text] [Related]
4. Docking Studies and Antiproliferative Activities of 6-(3-aryl-2-propenoyl)-2(3H)- benzoxazolone Derivatives as Novel Inhibitors of Phosphatidylinositol 3-Kinase (PI3Kα).
Bilginer S; Bardaweel SK; Sabbah DA; Gul HI
Anticancer Agents Med Chem; 2021; 21(6):716-724. PubMed ID: 32767959
[TBL] [Abstract][Full Text] [Related]
5. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.
Sabbah DA; Ibrahim AH; Talib WH; Alqaisi KM; Sweidan K; Bardaweel SK; Sheikha GA; Zhong HA; Al-Shalabi E; Khalaf RA; Mubarak MS
Med Chem; 2019; 15(4):417-429. PubMed ID: 30207238
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors.
Wu TT; Guo QQ; Chen ZL; Wang LL; Du Y; Chen R; Mao YH; Yang SG; Huang J; Wang JT; Wang L; Tang L; Zhang JQ
Eur J Med Chem; 2020 Oct; 204():112637. PubMed ID: 32717477
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer.
Wu CF; Wang QC; Chen R; Zhou HL; Wu TT; Du Y; Zhang NN; Zhang HM; Fan ZY; Wang LL; Hu CJ; Sang ZP; Li HL; Wang L; Tang L; Zhang JQ
Eur J Med Chem; 2022 Feb; 229():114055. PubMed ID: 34971874
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors.
Al-Ashmawy AAK; Ragab FA; Elokely KM; Anwar MM; Perez-Leal O; Rico MC; Gordon J; Bichenkov E; Mateo G; Kassem EMM; Hegazy GH; Abou-Gharbia M; Childers W
Bioorg Med Chem Lett; 2017 Jul; 27(14):3117-3122. PubMed ID: 28571824
[TBL] [Abstract][Full Text] [Related]
10. (
Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
[TBL] [Abstract][Full Text] [Related]
13. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing piperazine as inhibitors of PI3Kα.
Yin Y; Zhou Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
Bioorg Chem; 2019 Nov; 92():103238. PubMed ID: 31499259
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.
Lei F; Sun C; Xu S; Wang Q; OuYang Y; Chen C; Xia H; Wang L; Zheng P; Zhu W
Eur J Med Chem; 2016 Jun; 116():27-35. PubMed ID: 27043268
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of thieno[3,2-d]pyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors.
Yang X; Deng M; Zhang X; Wang Y; Song K; Cong R; Meng L; Zhang J
Chem Biol Drug Des; 2019 Dec; 94(6):2013-2022. PubMed ID: 30381889
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
Zhang B; Zhang Q; Xiao Z; Sun X; Yang Z; Gu Q; Liu Z; Xie T; Jin Q; Zheng P; Xu S; Zhu W
Bioorg Chem; 2020 Jan; 95():103525. PubMed ID: 31887474
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
Lv X; Ying H; Ma X; Qiu N; Wu P; Yang B; Hu Y
Eur J Med Chem; 2015 Jun; 99():36-50. PubMed ID: 26046312
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
Liu Y; Xia Q; Fang L
Bioorg Med Chem; 2018 Aug; 26(14):3992-4000. PubMed ID: 29945756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]